Obtaining marketing authorization does not mark the end of a medicine’s safety surveillance. Continuous pharmacovigilance monitoring is essential to detect, assess, and prevent potential safety signals throughout the product lifecycle. EudraVigilance is a key component of the European pharmacovigilance framework, serving as the centralized platform for the reporting and analysis of suspected adverse reactions.
What is EudraVigilance ?
EudraVigilance is the European database dedicated to the collection, management, and analysis of suspected adverse reactions related to medicinal products that are either authorized or under clinical investigation within the European Economic Area (EEA). Managed by the European Medicines Agency (EMA), the system centralizes safety reports reported across all EEA countries.
Whenever a healthcare professional, patient, or pharmaceutical company reports a suspected adverse reaction associated with a medicinal product, the information is entered into EudraVigilance for subsequent assessment by competent authorities.
Why is this system essential ?
EudraVigilance facilitates the electronic exchange of Individual Case Safety Reports (ICSRs) between the EMA, National Competent Authorities (NCA), and Marketing Authorization Holders (MAHs). In addition, the database supports:
- The early detection and evaluation of potential new safety signals associated with medicinal products;
- Enhanced knowledge and understanding of medicines authorized within the EEA.
Through the continuous review and analysis of collected data by the EMA and NCA, safety signal detection may lead to updates of product information, strengthened risk minimization measures, or changes to a product’s conditions of use.
The Pharmacovigilance Risk Assessment Committee (PRAC) evaluates the safety signals identified through EudraVigilance and may recommend regulatory actions when necessary.
What data are collected ?
EudraVigilance gathers various types of safety reports, including:
- Adverse reactions reported spontaneously by healthcare professionals and patients to NCA (e.g., ANSM in France);
- Cases identified through post-authorization studies;
- Cases described in the scientific literature;
- Safety events reported during clinical trials.
Who uses EudraVigilance ?
The database is used by several key stakeholders within the healthcare sector, including:
- National competent authorities;
- The EMA;
- Pharmaceutical companies holding marketing authorizations.
These stakeholders contribute to the database and participate in the continuous evaluation of the benefit-risk profile of medicinal products.
For pharmaceutical companies, electronic reporting of ICSRs to EudraVigilance is mandatory for both MAHs and clinical trial sponsors. The submission of pharmacovigilance cases, data quality management, compliance with reporting timelines, and signal detection activities are all critical components of ensuring regulatory compliance and safeguarding patient safety.
Effective management of EudraVigilance-related processes requires specialized expertise in pharmacovigilance, European pharmaceutical regulations, and safety data management systems.
To conclude, EudraVigilance is a cornerstone of the European pharmacovigilance system. By centralizing adverse reaction reports and facilitating their analysis, it enables the early identification of potential safety signals and contributes significantly to patient safety. Through this continuous monitoring process, competent authorities and pharmaceutical companies have access to an essential tool for ensuring the safe use of medicines throughout their lifecycle.
ATESSIA’s consultants support you across all pharmacovigilance activities, including compliance with European EudraVigilance requirements, ICSR management, pharmacovigilance process optimization, and the development of your pharmacovigilance teams’ expertise.
Article written by Marion PETOT, Pharmacovigilance Consultant